\n\n\n\n\t\t\n\t\t\tPulmonX\n\t\t\thttp://www.pulmonx.com/\n\t\t
\n\t\t\n\t\t\tWatch Company\n\t\t\tGet Widget\n\t\t
\n\tPulmonx is a C-stage start-up medical device company with a front runner position in the race to develop a treatment for emphysema. The company enjoys a compelling patent position in this space and is...More»
\n\t\t\tPulmonx is a C-stage start-up medical device company with a front runner position in the race to develop a treatment for emphysema. The company enjoys a compelling patent position in this space and is currently in early clinical trials. Early results are extremely promising. The company expects to successfully hit clinical trial milestones in the near future and will start to prepare for commercialization of the procedure and devices. Pulmonx will eventually build two different product groups with its airway management technology. The company\'s biggest business will come from the disposable optical airway catheters that are currently part of the LungPort system. In addition, Pulmonx is developing a reusable device. Pulmonx\'s first target in this area is a system that can transform lung volume reduction from a surgical procedure, as it\'s currently performed, to being capable of accomplished intra-bronchially, using an over-the-guidewire delivery system, as in interventional cardiology.«Less
\n\n\t\t\tOverview
\n\t\t\t\tLocation: \tPalo Alto, CA, United States\n
\n\t\t\t\tIndustry: Medical Devices & Equipment
\n\t\t\t\tTags:\n\t\t\t\tmedical,\n\t\t\t\temphysema,\n\t\t\t\tclinical,\n\t\t\t\tcatheters,\n\t\t\t\tairway\n\t\t\t\t
\n\t\t\tFinancials
\n\t\t\t\tLatest Funding: Debt - $11.5M (01/2010)
\n\t\t\t\tInvestors:\n\t\t\t\t\t\n\t\tDe Novo Ventures,\n\t\t\t\t\t\n\t\tLatterell Venture Partners,\n\t\t\t\t\t\n\t\tMedVenture Associates,\n\t\t\t\t\t\n\t\tMontreux Equity Partners\n\t\t\t\t
\n\t\t\t